<DOC>
	<DOCNO>NCT01149629</DOCNO>
	<brief_summary>One purpose study determine take droxidopa eating effect body process ( absorbs eliminates ) drug healthy elderly subject . Another purpose study see body process ( absorb eliminates ) one 300mg capsule compare three 100mg capsule . This study also evaluate well body process ( absorb eliminates ) tolerate droxidopa 300 mg capsule give 3 time day total dose 900 mg course one day . Droxidopa use treat low blood pressure upon stand patient diseases nervous system , prevent low blood pressure patient kidney disease hemodialysis ( removal waste product blood ) , treat frozen gait ( walk , step run ) dizziness upon stand patient Parkinson 's disease .</brief_summary>
	<brief_title>Study Fed-Fast Pharmocokinetics Bioequivalance 300mg Capsules Droxidopa</brief_title>
	<detailed_description>This two-part study . Part I randomize , open-label , three-period crossover study 24 healthy , elderly , male female subject . Subjects allocate one three treatment sequence accord randomization schedule prepare prior start study . Each subject receive single , oral dose three 100 mg capsule droxidopa 240 mL water either fast state ( Treatment A ) immediately follow consumption standardize high-fat meal ( Treatment B ) single , oral dose one 300 mg capsule droxidopa 240 mL water fast state ( Treatment C ) Days 1 , 4 , 7 . Subjects discharge research clinic Day 8 complete posttreatment follow-up assessment return research clinic approximately 1 week later Part II study . Part II study open-label design subject receive three dos 300 mg droxidopa ( three 100 mg capsules/dose ) 4 hour interval follow concurrent 24 h period .</detailed_description>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<mesh_term>Droxidopa</mesh_term>
	<criteria>1 . Provide write consent IRBapproved Informed Consent Form ( ICF ) , prior studyspecific evaluation . Subjects ability read understand ICF , ask clarification study staff , able comply plan study procedure . 2 . Male female ≥65 year age . 3 . Body mass index ( BMI ) 18 35 kg/m2 , inclusive . 4 . If female , pregnant ( lactate ) , evidence negative serum pregnancy test , surgically sterile ( hysterectomy , bilateral ovariectomy , bilateral tubal ligation ) , least 2 year postmenopausal . 5 . Ability willingness abstain alcohol 48 h prior first dose completion study . 6 . No clinically significant abnormality basis medical history , physical examination , vital sign unless currently control medical treatment ( e.g. , stable medication dose regimen ) . 7 . Computerized , 12lead ECG record without sign clinically relevant pathology show clinically relevant deviation , judge investigator . 8 . All value hematology , clinical chemistry , urinalysis normal abnormal—are deem clinically significant judged physician investigator document agreement Medical Monitor . 9 . Nonsmoking quit smoking least 6 month prior dose . 1 . Presence active recur clinically significant cardiovascular , pulmonary , renal , endocrine , hepatic , neurologic , psychiatric , immunologic , hematologic , gastrointestinal , metabolic disease currently control medical treatment ( e.g. , stable medication dose regimen ) . 2 . Presence active malignancy type nonmelanomatous skin malignancy . 3 . History relevant drug and/or food allergy . 4 . Recent history ( past 5 year ) alcohol abuse drug addiction . 5 . Required use concomitant medication could confound PK safety evaluation , medication affect GI function ( include proton pump inhibitor metoclopramide ) vasoconstricting agent ( e.g. , ephedrine , dihydroergotamine , midodrine ) , triptans ( e.g. , sumatriptan , naratriptan , zolmitriptan , rizatriptan ) , halogencontaining anesthetic ( e.g. , cyclopropane , halothane ) , catecholaminecontaining preparation ( e.g. , isoprenaline ) , nonselective MAOIs , ergotamine derivative ( except antiParkinson medication ) , drug antihypertensive property investigator 's opinion , could significantly contribute subject 's orthostatic hypotension . 6 . Participation investigational drug study within 30 day prior study drug administration . 7 . Donated unit blood ( 500 mL ) plasma within 30day period prior initial dose study medication intend donate blood plasma within 30day period follow final dose study medication . 8 . Positive screen drug abuse ( opiate , methadone , cocaine , amphetamine , cannabinoids , barbiturate , benzodiazepine ) alcohol . 9 . Positive screen urine cotinine . 10 . Positive screen hepatitis B surface antigen . 11 . Positive screen antibody hepatitis C virus . 12 . Positive screen antibody human immunodeficiency virus ( HIV1/HIV2 ) . 13 . Acute illness within 5 day prior drug administration . 14 . History coagulation disorder , thrombocytopenia , bleed tendency , gastrointestinal bleeding . 15 . Professional ancillary personnel involve study . 16 . In opinion investigator , suitable entry study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Droxidopa</keyword>
	<keyword>Randomized</keyword>
	<keyword>Crossover</keyword>
	<keyword>Open Label</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Fed Fast</keyword>
	<keyword>TID</keyword>
</DOC>